Abraham Ceesay, Rapport Therapeutics CEO

Neu­ro­science com­pa­ny Rap­port Ther­a­peu­tics lists on Nas­daq

Rap­port Ther­a­peu­tics ex­pects to raise $154 mil­lion from its ini­tial pub­lic of­fer­ing and a con­cur­rent stock sale to pri­vate in­vestors, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.